Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06254807 · ClinicalTrials.gov registry record · Phase 1
CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors
A Phase 1 study of HER2-positive, sponsored by Carisma Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06254807 is a Phase 1 study of HER2-positive that is active but no longer recruiting, run by Carisma Therapeutics. The registered enrollment target is 6 participants, below the 63-participant average among 3 other HER2-positive trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06254807, a Phase 1 study of HER2-positive, is active but no longer recruiting, sponsored by Carisma Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first-in-human open-label study to evaluate the safety and tolerability, and manufacturing feasibility of anti-HER2 CAR-monocytes (CT-0525) in participants with locally advanced (unresectable) or metastatic solid tumors overexpressing HER2 whose disease has progressed on standard approved therapies.
Conditions Studied
Interventions
- DRUG CT-0525
Study Locations (1)
Ohio
- University of Cincinnati - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-01-08 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06254807
The ClinicalTrials.gov registry entry for NCT06254807 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 63-participant average among 3 other HER2-positive trials with a reported enrollment target (90% lower). The listed sponsor is Carisma Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HER2-positive appearing as the primary indexed condition, and to 1 intervention - of which CT-0525 is the first listed.
NCT06254807 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06254807 about?
NCT06254807 is a clinical study titled "CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors". This is a first-in-human open-label study to evaluate the safety and tolerability, and manufacturing feasibility of anti-HER2 CAR-monocytes (CT-0525) in participants with locally advanced (unresectable) or metastatic solid tumors overexpressing HER2 whose disease has progressed on standard approved ...
What is the current status of trial NCT06254807?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2024-01-08. Estimated completion is 2026-03-31.
What conditions does trial NCT06254807 study?
This clinical trial studies the following conditions: HER2-positive.
What interventions are being tested in trial NCT06254807?
The interventions under investigation include: CT-0525 (DRUG).
Who is sponsoring clinical trial NCT06254807?
This trial is sponsored by Carisma Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06254807 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.